TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32446979
Drug: Xinyue capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xinyue capsule (100 mg panax quinquefolius saponins, three times a day)
Study: 32446979
Drug: Xinyue capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xinyue capsule
Study: 36259542
Drug: Ad26.RSV.preF vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad26.RSV.preF vaccine (1 × 10^11 vp for adults, 5 × 10^10 vp for children)
Study: 36259542
Drug: Ad26.RSV.preF vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad26.RSV.preF vaccine
Study: 33217865
Drug: Medicine group
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medicine group
Study: 35473351
Drug: Time-acupoints-space acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time-acupoints-space acupuncture (ATAS) administered weekly
Study: 33439693
Drug: Atezolizumab (1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab (1,200 mg IV, day 1) plus carboplatin (AUC 5 mg/mL/min IV, day 1) and etoposide (100 mg/m2 IV, days 1-3)
Study: 33439693
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus carboplatin (AUC 5 mg/mL/min IV, day 1) and etoposide (100 mg/m2 IV, days 1-3)
Study: 35848580
Drug: Structured physiotherapy
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured physiotherapy along with conventional treatment
Study: 36176043
Drug: Low-dose-rate brachytherapy
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose-rate brachytherapy (LDR-BT)
Study: 36334130
Drug: rHuEPO (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuEPO (20 IU/kg body weight) i.v. injections
Study: 33515707
Drug: Qizhitongluo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qizhitongluo capsule (QZTL)
Study: 34325540
Drug: Tablets without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets without any bacteria (Control)
Study: 35397772
Drug: Enzalutamide (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzalutamide (160 mg/day)
Study: 34339227
Drug: Discontinuing β-lactam
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuing β-lactam treatment after 3 days
Study: 34339227
Drug: Continuing β-lactam
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuing β-lactam treatment for 5 additional days
Study: 35386854
Drug: Nalbuphine 0.280
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine 0.280 mg/kg
Study: 35386854
Drug: Nalbuphine 0.200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine 0.200 mg/kg
Study: 35386854
Drug: Nalbuphine 0.140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine 0.140 mg/kg
Study: 35386854
Drug: Nalbuphine 0.070
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine 0.070 mg/kg
Study: 35386854
Drug: Nalbuphine 0.100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine 0.100 mg/kg
Study: 35898865
Drug: Pulmonary metastasectomy
Normalized name: Lobaria pulmonaria extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulmonary metastasectomy plus standard medical treatment
Study: 35898865
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical treatment plus possible local ablative measures (e.g., SBRT)
Study: 33170934
Drug: Azacitidine maintenance
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine maintenance (32 mg/m2 per day subcutaneously for 5 days every 28 days for 12 cycles)
Study: 32265361
Drug: Immediate oral
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate oral etoposide
Study: 33423518
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of abnormal physiological parameters and warfarin use
Study: 32788479
Drug: Infusion giving
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infusion giving set
Study: 34781708
Drug: Cilostazol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilostazol (200 mg once daily for 2 years)
Study: 34781708
Drug: Aspirin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (100 mg once daily for 2 years)
Study: 33297730
Drug: Psychoeducational relaxation
Normalized name: Relax-DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychoeducational relaxation therapy (PRT, n=84)
Study: 37149458
Drug: Avelumab maintenance
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avelumab maintenance therapy
Study: 33512754
Drug: Licogliflozin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licogliflozin (50 mg once daily)
Study: 32743852
Drug: Antidiabetic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidiabetic drugs
Study: 33075807
Drug: Kisspeptin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kisspeptin (1 nmol/kg/h intravenous infusion over 75 minutes)
Study: 33075807
Drug: Vehicle (rate‐matched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle (rate‐matched infusion)
Study: 33866916
Drug: Isotretinoin treatment
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isotretinoin treatment (mean daily dose 38.7 ± 2.8 mg for 7.20 ± 0.79 months)
Study: 32776169
Drug: Robot-assisted gait
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robot-assisted gait training for 2 weeks followed by conventional therapy for 2 weeks
Study: 32776169
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy for 2 weeks followed by robot-assisted gait training for 2 weeks
Study: 32776169
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy followed by robot-assisted gait training
Study: 34881844
Drug: Subepithelial connective
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subepithelial connective tissue graft (SCTG) followed by orthodontic treatment
Study: 34881844
Drug: Orthodontic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orthodontic treatment only
Study: 35916932
Drug: Educational intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Educational intervention based on the theory of planned behavior (TPB), consisting of six weekly sessions.
Study: 33976287
Drug: Convalescent plasma
Normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Convalescent plasma therapy (two 200 ml transfusions over 24 hours)
Study: 33377451
Drug: Low-dose dexamethasone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dexamethasone (oral or intravenous) in adults with COVID-19 requiring oxygen or mechanical ventilation
Study: 33377451
Drug: Alternate equivalent
Normalized name: Alternaria alternata
DrugBank: Alternaria alternata (DB10424)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternate equivalent doses of steroids
Study: 33377451
Drug: Interleukin-6 inhibitors
Normalized name: interleukin-6
DrugBank: Human interleukin-6 (DB15060)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interleukin-6 inhibitors (e.g., tocilizumab)
Study: 33377451
Drug: Empiric antimicrobial
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empiric antimicrobial treatment for likely coinfecting pathogens
Study: 34587384
Drug: Maintenance group
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance group (continued antidepressant therapy)
Study: 34587384
Drug: Discontinuation group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation group (taper and discontinue therapy with placebo)
Study: 34587384
Drug: Discontinuation group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation group
Study: 33267539
Drug: Intramuscular injections
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injections of muramylpeptide composition
Study: 33267539
Drug: Oral hygiene
Normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hygiene instructions, professional oral hygiene procedures, and root scaling
Study: 34711479
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g L-Citrulline
Study: 32645159
Drug: Advanced reproductive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advanced reproductive age associated with hemoglobin (≥12 vs <12 g/dL)
Study: 35278844
Drug: IV Morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Morphine
Study: 35101958
Drug: Intravenous thrombolysis
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous thrombolysis (IVT) preceding IAT
Study: 33991310
Drug: Nitazoxanide 500
Normalized name: nitazoxanide 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitazoxanide 500 mg BD per oral for 10 days
Study: 33991310
Drug: Metronidazole 2-2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 2-2.5 g/day IV for inpatients or 2-2.4 g/day oral for outpatients for 14 days
Study: 35476706
Drug: Extended antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended antibiotic course (13-14 days duration)
Study: 35476706
Drug: Standard antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antibiotic course (5-6 days duration)
Study: 34229149
Drug: amoxicillin plus
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: amoxicillin plus prednisolone
Study: 34229149
Drug: metamizole/acetaminophen
Approvals — FDA: no, EMA: no, PMDA: no
Description: metamizole/acetaminophen
Study: 33350170
Drug: Cyclophosphamide (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide (placebo treatment period)
Study: 35502452
Drug: Coaching program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coaching program (physical activity, home visits, weekly phone calls)
Study: 34182603
Drug: High-flow nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow nasal oxygen up to 60 l.min-1 at 100% FIO2
Study: 34182603
Drug: Low-flow nasal
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-flow nasal oxygen at 4 l.min-1 plus oxygen through an oxygenating mouthguard totalling 8 l.min-1
Study: 33858441
Drug: Low sulfur
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low sulfur amino acid (SAA) diet (total diet SAA 15–25 mg/kg body weight/day)
Study: 33858441
Drug: High sulfur
Approvals — FDA: no, EMA: no, PMDA: no
Description: High sulfur amino acid (SAA) diet (total diet SAA 50–60 mg/kg body weight/day)
Study: 33439140
Drug: Sanadak app
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sanadak app (cognitive behavioral therapy-based self-help)
Study: 35267246
Drug: Luseogliflozin (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luseogliflozin (2.5 mg, once daily)
Study: 35267246
Drug: Voglibose (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voglibose (0.2 mg, three times daily)
Study: 36277941
Drug: Weekly voice
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly voice message intervention transmitted through mobile phone from recruitment in the first trimester until two weeks postpartum.
Study: 34474578
Drug: Passive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passive treatment and education
Study: 32452142
Drug: Female hormones
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Female hormones users
Study: 33006952
Drug: Electrical vestibular
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Electrical vestibular nerve stimulation (VeNS) administered for 30 minutes, 1 hour prior to sleep onset for 14 days using ML1000 device (Neurovalens, UK)
Study: 34448694
Drug: Test preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test preparation (250 mg) in fasting group
Study: 34448694
Drug: Reference preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference preparation (250 mg) in fasting group
Study: 34448694
Drug: Test preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test preparation (250 mg) in postprandial group
Study: 34448694
Drug: Reference preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference preparation (250 mg) in postprandial group
Study: 32746952
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g daily of 99% cocoa chocolate for 6 months
Study: 35151410
Drug: Balovaptan (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balovaptan (10 mg daily for 24 weeks)
Study: 32697556
Drug: 0.5% timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% timolol maleate administered by a trained clinician
Study: 36314321
Drug: Omega-3 +
Normalized name: Walgreens Finest Nutrition OMEGA-3 + D Softgel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 + standard therapy (hydroxyurea and folic acid daily with ibuprofen as needed)
Study: 36314321
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D + standard therapy (hydroxyurea and folic acid daily with ibuprofen as needed)
Study: 34632922
Drug: Proton therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton therapy (50 Gy in 25 fractions)
Study: 34632922
Drug: Proton therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton therapy (40 Gy in 15 fractions)
Study: 34632922
Drug: Proton therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton therapy with anatomical evaluation
Study: 32456617
Drug: DL-3-n-butylphthalide (NBP)
Normalized name: DL-3-n-butylphthalide
DrugBank: Butylphthalide (DB12749)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DL-3-n-butylphthalide (NBP) 200 mg three times daily for four weeks
Study: 32456617
Drug: Placebo 20
Normalized name: Ethinyl Estradiol/Norethindrone Acetate;Placebo 20 MCG-1 MG; NA Oral Tablet, Disintegrating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 20 mg three times daily for four weeks
Study: 32811342
Drug: Radioiodine (RAI)
Normalized name: Radioiodine
DrugBank: Iodide I-131 (DB09293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioiodine (RAI) treatment, fixed dose of 15 mCi
Study: 32811342
Drug: Long-term Methimazole
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term Methimazole (MMI) treatment, starting dose of 10 mg daily, decreased to 4.9±1.0, 4.3±1.0, 4.4±1.4, 4.3±1.8, and 3.7±1.3 mg after 1, 2, 3, 4, and 5 years respectively
Study: 32051177
Drug: AI2 personal
Approvals — FDA: no, EMA: no, PMDA: no
Description: AI2 personal nudging system (text messages for missed medications or health checks)
Study: 33960149
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of empagliflozin for 12 weeks
Study: 33387427
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy only in 20 patients (comparison group).
Study: 32948554
Drug: 500 mL
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mL of intravenous crystalloid
Study: 32948554
Drug: No intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intravenous fluid bolus
Study: 35276967
Drug: Rice bran
Normalized name: Rice bran
DrugBank: Rice bran (DB14361)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rice bran supplementation (1–5 g/day for 6 months)
Study: 32180155
Drug: BoNT‐A injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: BoNT‐A injection into the pectoralis major and teres major muscles
Study: 33401219
Drug: Atorvastatin (ATORVA)
Normalized name: atorvastatin Oral Suspension [Atorvaliq]
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin (ATORVA) 40 mg daily for 6 months
Study: 33401219
Drug: Rosuvastatin (ROSUVA)
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin (ROSUVA) 10 mg daily for 6 months
Study: 32134758
Drug: Intracoronary Adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary Adenosine (two bolus doses)
Study: 32295779
Drug: Psychotherapy as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotherapy as treatment as usual
Study: 34569538
Drug: CMV‐HyperIg treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMV‐HyperIg treatment upon seroconversion
Study: 36217901
Drug: RP7214 single-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: RP7214 single-dose (100, 200, and 400 mg QD)
Study: 36217901
Drug: RP7214 food
Approvals — FDA: no, EMA: no, PMDA: no
Description: RP7214 food effect (single dose of 200 mg)
Study: 35536579
Drug: Community and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community and clinic education intervention program (Ask About Aspirin campaign)
Study: 36086876
Drug: Steroid-eluting stents
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid-eluting stents containing mometasone furoate
Study: 36086876
Drug: Control side
Normalized name: cured fat, pork side bacon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control side (no steroid-eluting stents)
Study: 32622913
Drug: eGFR≤30 mL/min/1.73m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: eGFR≤30 mL/min/1.73m2 or renal replacement therapy
Study: 34033120
Drug: Bifonazole solution
Normalized name: bifonazole
DrugBank: Bifonazole (DB04794)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifonazole solution
Study: 35590347
Drug: Low intensity
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low intensity (once daily) CTAR‐SwiFt exercise
Study: 35590347
Drug: High intensity
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High intensity (twice daily) CTAR‐SwiFt exercises
Study: 34271953
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of Astragalus Membranaceus Root (AMR)
Study: 32162497
Drug: Experimental transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental transdermal gel (ETG)
Study: 32162497
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel (PTG)
Study: 32162497
Drug: Complete multimodal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complete multimodal treatment (ETG + external therapies, art therapies, neurofunctional reorganization)
Study: 32162497
Drug: Weekly external
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly external therapies, art therapies, and neurofunctional reorganization with ETG
Study: 615270428
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of unruptured AVMs grade 1 and 2
Study: 615270428
Drug: Treatment strategy
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment strategy defined by multidisciplinary team
Study: 32020565
Drug: Prolonged-release oxycodone/naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged-release oxycodone/naloxone (OXN PR)
Study: 32020565
Drug: Prolonged-release oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged-release oxycodone (OXY PR)
Study: 33730384
Drug: CBT4CBT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBT4CBT plus treatment as usual (CBT4CBT+TAU)
Study: 32842839
Drug: Culturally-adapted treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culturally-adapted treatment (CAT)
Study: 32842839
Drug: Standard evidence-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard evidence-based treatment (EBT)
Study: 35934663
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment for OAB)
Study: 32776430
Drug: One cup
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One cup of espresso coffee plus two CBPCC twice per day
Study: 32460699
Drug: Dexmedetomidine (DEX)
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine (DEX) 0.4 μg/kg over 10 mins followed by 0.4 μg/kg/h till the second day morning after surgery
Study: 32460699
Drug: Placebo (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (normal saline) administered similarly to DEX group
Study: 32945145
Drug: Psychological interventions
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Psychological interventions (CBT and CBT + add on treatment)
Study: 32945145
Drug: More than
Normalized name: polyurethane-35 (not more than MPA.S at 40 %)
Approvals — FDA: no, EMA: no, PMDA: no
Description: More than 20 treatment sessions
Study: 32579776
Drug: JNJ-56136379 (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-56136379 (25 mg)
Study: 32579776
Drug: JNJ-56136379 (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-56136379 (75 mg)
Study: 32579776
Drug: JNJ-56136379 (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-56136379 (150 mg)
Study: 34086631
Drug: 800-mg orally
Normalized name: piracetam 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800-mg orally administered CBD
Study: 32648983
Drug: Ketamine mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine mouthwash (4 mg/mL solution; dose 1 mg/kg)
Study: 33374970
Drug: Low-iron formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-iron formula (2 mg/L) fortified with bovine lactoferrin (1.0 g/L)
Study: 33374970
Drug: Low-iron formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-iron formula unfortified with lactoferrin (2 mg/L)
Study: 33374970
Drug: Standard formula
Normalized name: Standard formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard formula with 8 mg of iron/L and no lactoferrin fortification (Control)